These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 32154922)

  • 1. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
    Dhakal B; Narra RK; Giri S; Szabo A; Smunt TL; Ghose S; Pathak LK; Aryal M; Hamadani M; Chhabra S; Janz S; D'Souza A; Hari PN
    Cancer; 2020 Jun; 126(12):2791-2801. PubMed ID: 32154922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
    Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
    Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.
    Hansen DK; Lu X; Puglianini OC; Sorensen S; Usmani SZ; Zhang E; Huo S; Zhang Y; Qureshi ZP; Jagannath S
    Front Immunol; 2024; 15():1408892. PubMed ID: 39234256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
    van Beurden-Tan CHY; Franken MG; Blommestein HM; Uyl-de Groot CA; Sonneveld P
    J Clin Oncol; 2017 Apr; 35(12):1312-1319. PubMed ID: 28240968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.
    Giri S; Aryal MR; Yu H; Grimshaw A; Pathak R; Huntington SP; Dhakal B
    J Geriatr Oncol; 2020 Nov; 11(8):1285-1292. PubMed ID: 32513568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
    Laubach JP; Schjesvold F; Mariz M; Dimopoulos MA; Lech-Maranda E; Spicka I; Hungria VTM; Shelekhova T; Abdo A; Jacobasch L; Polprasert C; Hájek R; Illés Á; Wróbel T; Sureda A; Beksac M; Gonçalves IZ; Bladé J; Rajkumar SV; Chari A; Lonial S; Spencer A; Maison-Blanche P; Moreau P; San-Miguel JF; Richardson PG
    Lancet Oncol; 2021 Jan; 22(1):142-154. PubMed ID: 33301738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
    Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
    Chen H; Chen H; Zhou Y; Xu W; Yu J; Xu Y; Zhou F
    Hematology; 2023 Dec; 28(1):2225342. PubMed ID: 37343159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
    Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
    Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
    J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
    Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K
    Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
    Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis.
    Luo XW; Du XQ; Li JL; Liu XP; Meng XY
    Cancer Manag Res; 2018; 10():2817-2823. PubMed ID: 30174457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
    Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
    J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
    Cao Y; Wan N; Liang Z; Xie J; Wang S; Lin T; Zhang T; Jiang J
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e478-e488. PubMed ID: 31130487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.